Bispezifische Antikörper und CAR-T-Zellen

Assoc.-Prof.ⁱⁿ Priv.-Doz.ⁱⁿ Dr.ⁱⁿ Maria Krauth stellt in diesem Beitrag mehrere Highlights der Immuntherapie beim Multiplen Myelom vor. Dabei wird der Bogen von den bispezifischen Antikörpern Teclistamab, Talquetamab und Elranatamab bis zu den CAR-T-Zelltherapien Idecabtagen-Vicleucel (Ide-cel) und Ciltagabtagen-Autoleucel (Cilta-cel) gespannt. Besonders hervorzuheben sind auch Ergebnisse der Kombinationsstudien mehrerer Immuntherapien miteinander, wie die Kombination aus Teclistamab und Talquetamab in der REDIRECTT-1-Studie oder Talquetamab und Daratumumab in der TRIMM-2-Studie.

PIVOTAL PHASE 2 MONUMENTAL-1 RESULTS OF TALQUETAMAB (TAL), AGPRC5DXCD3 BISPECIFIC ANTIBODY (BSAB), FOR RELAPSED/REFRACTORYMULTIPLE MYELOMA (RRMM), Touzeau C et al., S191

FIRST RESULTS FROM THE REDIRECTT-1 STUDY WITH TECLISTAMAB (TEC) + TALQUETAMAB (TAL) SIMULTANEOUSLY TARGETING BCMA AND GPRC5D IN PATIENTS (PTS) WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM), Mateos MV et al., S190

TALQUETAMAB (TAL) + DARATUMUMAB (DARA) IN PATIENTS (PTS) WITHRELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): UPDATED TRIMM-2 RESULTS, Bahlis NJ et al., S192

ELRANATAMAB, A B-CELL MATURATION ANTIGEN (BCMA)-CD3 BISPECIFICANTIBODY, FOR PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA:EXTENDED FOLLOW UP AND BIWEEKLY ADMINISTRATION FROM MAGNETISMM-3, Mohty M et al., S196

EFFICACY AND SAFETY OF ELRANATAMAB IN PATIENTS WITHRELAPSED/REFRACTORY MULTIPLE MYELOMA AND PRIOR B-CELL MATURATIONANTIGEN (BCMA)-DIRECTED THERAPIES: A POOLED ANALYSIS FROMMAGNETISMM STUDIES, Manier S et al., P870

EFFICACY AND SAFETY OF ELRANATAMAB BY AGE AND FRAILTY INPATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): ASUBGROUP ANALYSIS FROM MAGNETISMM-3, Leleu X et al., P880

EFFICACY AND SAFETY OF ELRANATAMAB IN HIGH-RISK PATIENTS WITHRELAPSED/REFRACTORY MULTIPLE MYELOMA: A SUBGROUP ANALYSIS FROMMAGNETISMM-3, Touzeau C et al., P907

BMS-986393 (CC-95266), A G PROTEIN–COUPLED RECEPTOR CLASS C GROUP5 MEMBER D (GPRC5D)–TARGETED CAR T-CELL THERAPY FORRELAPSED/REFRACTORY MULTIPLE MYELOMA (RRMM): RESULTS FROM A PHASE 1STUDY, Bal S et al., S193

CARTITUDE-1 FINAL RESULTS: PHASE 1B/2 STUDY OF CILTACABTAGENEAUTOLEUCEL IN HEAVILY PRETREATED PATIENTS WITH RELAPSED/REFRACTORYMULTIPLE MYELOMA, Munshi N et al., S202

IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN PATIENTSWITH TRIPLE-CLASS–EXPOSED (TCE) RELAPSED AND REFRACTORY MULTIPLEMYELOMA (RRMM): A KARMMA-3 ANALYSIS IN HIGH-RISK SUBGROUPS, Patel K et al., S195